BlackRock Amends Allogene Therapeutics Stake, Remains Passive Investor
Ticker: ALLO · Form: SC 13G/A · Filed: Jan 29, 2024 · CIK: 1737287
| Field | Detail |
|---|---|
| Company | Allogene Therapeutics, Inc. (ALLO) |
| Form Type | SC 13G/A |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock still owns a chunk of Allogene, but they're just holding, not shaking things up.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 29, 2024, disclosing its ownership in Allogene Therapeutics, Inc. as of December 31, 2023. This filing indicates BlackRock's continued significant, but passive, investment in Allogene Therapeutics, a biotechnology company. For investors, this means a major institutional player maintains a stake, which can signal confidence, but the 'passive' nature suggests they aren't looking to influence company management.
Why It Matters
This filing confirms BlackRock's ongoing, substantial investment in Allogene Therapeutics, providing a degree of institutional validation for current and prospective shareholders.
Risk Assessment
Risk Level: low — This filing is routine and indicates a passive investment, posing minimal direct risk to the company or its shareholders.
Analyst Insight
Investors should note BlackRock's continued passive stake in Allogene Therapeutics, which suggests long-term institutional interest without any immediate activist intentions. This information can be factored into a broader analysis of institutional ownership and market sentiment for Allogene Therapeutics.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Allogene Therapeutics, Inc. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 29, 2024 (date) — the filing date of the SC 13G/A
- 019770106 (other) — the CUSIP number for Allogene Therapeutics Common Stock
FAQ
What type of filing is this and what does it generally indicate?
This is an SC 13G/A filing, which is an amendment to a Schedule 13G. It generally indicates that a passive institutional investor, like BlackRock Inc., owns more than 5% of a company's stock and is updating their ownership information.
Who is the reporting person in this filing?
The reporting person is BlackRock Inc., a major asset management firm, as stated in the 'Names of reporting persons' section of the filing.
What is the subject company whose shares are being reported?
The subject company is Allogene Therapeutics, Inc., a biotechnology company, as identified in the 'Name of Issuer' section.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, as explicitly stated in the filing.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), indicated by the '[X] Rule 13d-1(b)' checkbox on the cover page.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 29, 2024 regarding Allogene Therapeutics, Inc. (ALLO).